Simulations Plus (NASDAQ:SLP) Updates FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.070-1.200 for the period, compared to the consensus estimate of 1.090. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.4 million. Simulations Plus also updated its FY25 guidance to $1.07-1.20 EPS.

Wall Street Analyst Weigh In

Several analysts have issued reports on SLP shares. KeyCorp boosted their price target on Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a report on Friday, January 24th. StockNews.com upgraded Simulations Plus from a "sell" rating to a "hold" rating in a research note on Friday. Finally, William Blair restated an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Simulations Plus Trading Down 2.3 %

SLP traded down $0.58 on Tuesday, hitting $24.25. 275,469 shares of the company's stock traded hands, compared to its average volume of 175,875. The company's 50 day simple moving average is $29.46 and its 200-day simple moving average is $30.13. Simulations Plus has a one year low of $23.01 and a one year high of $51.22. The firm has a market cap of $487.23 million, a price-to-earnings ratio of 60.63 and a beta of 1.13.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The firm had revenue of $22.43 million for the quarter, compared to analysts' expectations of $21.93 million. During the same quarter last year, the business posted $0.20 earnings per share. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, equities analysts anticipate that Simulations Plus will post 1.09 EPS for the current fiscal year.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the sale, the director now directly owns 3,402,584 shares of the company's stock, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 19.40% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.